HOME >> BIOLOGY >> NEWS
Breast cancer follow-ups 'no longer guess-work' thanks to new physics research

As the number of breast cancer patients rises, and hospitals struggle to meet the growing cost of healthcare provision, new research by physicists could help divert funds into frontline treatment such as chemotherapy drugs and better imaging technology.

Breast cancer is the most common form of cancer in England and Wales and one in nine women will develop breast cancer at some point in their lives. Research published today (Monday 1st March 2004) in the Institute of Physics journal Physics in Medicine & Biology reveals a new technique that will help doctors to judge more accurately how long they should continue to see patients following successful treatment of breast cancer. Doctors currently see patients for follow-up examinations for up to ten years in order to check for recurrence of the tumour. Until now, this length time (the "follow-up period") has been guess-work by doctors, and is generally much longer than necessary.

Dr. Richard Mould, the lead author of the paper, said: "Doctors tend to follow-up cancer patients for much longer than is really necessary, using hospital resources that could be better spent on frontline treatment such as chemotherapy drugs and better imaging technology in hospitals."

He continued: "This is the first time scientists have produced a formal way of calculating a precise length of follow-up needed, and it can be specific to a particular hospital or region. Our study suggests that follow up times can be reduced from ten years to four years without significantly reducing our ability to detect local tumour reccurrance. This means that six years worth of a physician's time and outpatient clinic costs could instead be diverted to parts of the treatment process where it would do more good."

Using data taken from a series of patients with T1 and T2 stage (primary tumours up to 5cm in greatest dimension) breast cancer from the Institut Curie in Paris, Dr. Mould developed a model which involves calcu
'"/>

Contact: David Reid
david.reid@iop.org
44-207-470-4815
Institute of Physics
1-Mar-2004


Page: 1 2

Related biology news :

1. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
2. Breastfeeding decreases infant mortality
3. Breast cancer study suggests role for tissue in carcinogenesis
4. Breast self examination increases womens concerns but has no effect on mortality
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Sangamo BioSciences, ... genome editing, announced today that Edward Lanphier , ... update on the progress of Sangamo,s ZFP Therapeutic ® ... business strategy at 2:40 pm ET on Thursday, February ... Annual Global Healthcare Conference. The conference is being held ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation ... leader commercializing its flagship CytoSorb® blood filter to ... patients around the world, announced that CEO Dr. ... at the Source Capital Group,s 2016 Disruptive Growth ... on the company.  Conference Presentation ...
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
Breaking Biology Technology:
Cached News: